stem-cells-istock-577639302_posteriori

posteriori / iStockphoto.com

26 February 2018Americas

Kite teams up with Sangamo to treat cancer

Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

More on this story

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

More on this story

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York